Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure

Descripción del Articulo

El texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado.
Detalles Bibliográficos
Autores: Nagarajan, Vijaiganesh, Hernandez, Adrian V., Cauthen, Clay A., Starling, Randall C., Tang, W. H. Wilson
Formato: artículo
Fecha de Publicación:2017
Institución:Universidad Peruana de Ciencias Aplicadas
Repositorio:UPC-Institucional
Lenguaje:inglés
OAI Identifier:oai:repositorioacademico.upc.edu.pe:10757/622259
Enlace del recurso:https://doi.org/10.1016/j.ahj.2016.09.008
http://hdl.handle.net/10757/622259
Nivel de acceso:acceso abierto
Materia:Acetylsalicylic acid
Angiotensin receptor antagonist
Beta adrenergic receptor blocking agent
Clopidogrel
Dipeptidyl carboxypeptidase inhibitor
Hydralazine
nitric acid derivative
Phytohemagglutinin
Spironolactone
id UUPC_6823465be271b9e72fbdf57366c07423
oai_identifier_str oai:repositorioacademico.upc.edu.pe:10757/622259
network_acronym_str UUPC
network_name_str UPC-Institucional
repository_id_str 2670
dc.title.es.fl_str_mv Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure
title Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure
spellingShingle Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure
Nagarajan, Vijaiganesh
Acetylsalicylic acid
Angiotensin receptor antagonist
Beta adrenergic receptor blocking agent
Clopidogrel
Dipeptidyl carboxypeptidase inhibitor
Hydralazine
nitric acid derivative
Phytohemagglutinin
Spironolactone
title_short Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure
title_full Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure
title_fullStr Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure
title_full_unstemmed Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure
title_sort Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure
author Nagarajan, Vijaiganesh
author_facet Nagarajan, Vijaiganesh
Hernandez, Adrian V.
Cauthen, Clay A.
Starling, Randall C.
Tang, W. H. Wilson
author_role author
author2 Hernandez, Adrian V.
Cauthen, Clay A.
Starling, Randall C.
Tang, W. H. Wilson
author2_role author
author
author
author
dc.contributor.email.es_PE.fl_str_mv tangw@ccf.org
dc.contributor.author.fl_str_mv Nagarajan, Vijaiganesh
Hernandez, Adrian V.
Cauthen, Clay A.
Starling, Randall C.
Tang, W. H. Wilson
dc.subject.es.fl_str_mv Acetylsalicylic acid
Angiotensin receptor antagonist
Beta adrenergic receptor blocking agent
Clopidogrel
Dipeptidyl carboxypeptidase inhibitor
Hydralazine
nitric acid derivative
Phytohemagglutinin
Spironolactone
topic Acetylsalicylic acid
Angiotensin receptor antagonist
Beta adrenergic receptor blocking agent
Clopidogrel
Dipeptidyl carboxypeptidase inhibitor
Hydralazine
nitric acid derivative
Phytohemagglutinin
Spironolactone
description El texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado.
publishDate 2017
dc.date.accessioned.none.fl_str_mv 2017-10-19T15:57:18Z
dc.date.available.none.fl_str_mv 2017-10-19T15:57:18Z
dc.date.issued.fl_str_mv 2017-01
dc.type.es.fl_str_mv info:eu-repo/semantics/article
dc.type.version.none.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a666
format article
dc.identifier.citation.es.fl_str_mv Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure 2017, 183:35 American Heart Journal
dc.identifier.issn.none.fl_str_mv 00028703
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1016/j.ahj.2016.09.008
dc.identifier.uri.none.fl_str_mv http://hdl.handle.net/10757/622259
dc.identifier.journal.es.fl_str_mv American Heart Journal
identifier_str_mv Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure 2017, 183:35 American Heart Journal
00028703
American Heart Journal
url https://doi.org/10.1016/j.ahj.2016.09.008
http://hdl.handle.net/10757/622259
dc.language.iso.es.fl_str_mv eng
language eng
dc.relation.url.es.fl_str_mv http://linkinghub.elsevier.com/retrieve/pii/S0002870316302046
dc.rights.es.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.es.fl_str_mv application/pdf
dc.publisher.es.fl_str_mv Mosby Inc.
dc.source.none.fl_str_mv reponame:UPC-Institucional
instname:Universidad Peruana de Ciencias Aplicadas
instacron:UPC
instname_str Universidad Peruana de Ciencias Aplicadas
instacron_str UPC
institution UPC
reponame_str UPC-Institucional
collection UPC-Institucional
bitstream.url.fl_str_mv https://repositorioacademico.upc.edu.pe/bitstream/10757/622259/1/license.txt
https://repositorioacademico.upc.edu.pe/bitstream/10757/622259/2/10.1016j.ahj.2016.09.008.pdf
https://repositorioacademico.upc.edu.pe/bitstream/10757/622259/3/10.1016j.ahj.2016.09.008.pdf.txt
https://repositorioacademico.upc.edu.pe/bitstream/10757/622259/4/10.1016j.ahj.2016.09.008.pdf.jpg
https://repositorioacademico.upc.edu.pe/bitstream/10757/622259/5/elsevier-thumbnail.png
bitstream.checksum.fl_str_mv 255616c2e22876c8a237cd50f1bc22a3
e6d01603d18f137819bac0da82c58978
d101c8f48d52110e2433ce03e252dfe3
7620e6f343bc063fc746055557d16a9b
77c7e9a562c4c4736093e27568f8f71a
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Académico UPC
repository.mail.fl_str_mv upc@openrepository.com
_version_ 1863822595374186496
spelling b8c1432aef89b9f26d0df9ec063d9198-1cc55c7c82f701158586b8e3771c56d81-13f2ec7a869d2137d6ae34ee1099dac1d-12acaa317535c6ca288638397a9b524bc-11743b45c4af5e4ae2da08c840b6102be-1Nagarajan, VijaiganeshHernandez, Adrian V.Cauthen, Clay A.Starling, Randall C.Tang, W. H. Wilsontangw@ccf.org2017-10-19T15:57:18Z2017-10-19T15:57:18Z2017-01Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure 2017, 183:35 American Heart Journal00028703https://doi.org/10.1016/j.ahj.2016.09.008http://hdl.handle.net/10757/622259American Heart JournalEl texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado.Although heightened inflammation and autoimmune responses have been well described in patients with heart failure, the role of cell-mediated immune function in the pathogenesis and progression of heart failure is unclear. The aim of our study is to evaluate the prognostic role of cell-mediated immune function in patients with advanced heart failure. Methods We studied patients with advanced heart failure referred for evaluation of candidacy for advanced heart failure therapies between 2007 and 2010. Cell-mediated immune response was categorized into 3 groups—low or poor immune response (≤225 ng/mL), moderate or normal immune response (226-524 ng/mL), and strong immune response (≥525 ng/mL)—using a phytohemagglutinin-stimulated T-cell response assay. Results Out of 368 patients, 41 patients (11.1%) had poor immune function, 258 patients (70.1%) had normal immune function, and 69 patients (18.7%) had strong immune function. The primary outcome of all-cause mortality or cardiac transplantation occurred in 63.4%, 45.3%, and 34.8% in the poor immunity, normal immunity, and strong immune function groups, respectively. In univariate analysis, cell-mediated immune function was strongly associated with the primary outcome (P =.014). Poor immune function portended worse prognosis (hazard ratio = 2.18, 95% CI 1.01-4.70, P =.047), and strong immune function was associated with better survival (hazard ratio = 0.67, 95% CI 0.43-1.04). However, when adjusted for multiple variables in multivariate analysis, immune function status lost its overall significance to predict primary outcome (P = 0.11), but the direction to an increased risk of primary outcome was maintained in the poor immune function group. Conclusions Poor cell-mediated immune function measured by a clinically available assay could be associated with more adverse long-term prognosis in patients with advanced heart failure. © 2016 Elsevier Inc.Revisión por paresapplication/pdfengMosby Inc.http://linkinghub.elsevier.com/retrieve/pii/S0002870316302046info:eu-repo/semantics/openAccessAcetylsalicylic acidAngiotensin receptor antagonistBeta adrenergic receptor blocking agentClopidogrelDipeptidyl carboxypeptidase inhibitorHydralazinenitric acid derivativePhytohemagglutininSpironolactoneUsefulness of cell-mediated immune function in risk stratification for patients with advanced heart failureinfo:eu-repo/semantics/articlehttp://purl.org/coar/version/c_970fb48d4fbd8a666reponame:UPC-Institucionalinstname:Universidad Peruana de Ciencias Aplicadasinstacron:UPC2018-06-17T23:29:26ZAlthough heightened inflammation and autoimmune responses have been well described in patients with heart failure, the role of cell-mediated immune function in the pathogenesis and progression of heart failure is unclear. The aim of our study is to evaluate the prognostic role of cell-mediated immune function in patients with advanced heart failure. Methods We studied patients with advanced heart failure referred for evaluation of candidacy for advanced heart failure therapies between 2007 and 2010. Cell-mediated immune response was categorized into 3 groups—low or poor immune response (≤225 ng/mL), moderate or normal immune response (226-524 ng/mL), and strong immune response (≥525 ng/mL)—using a phytohemagglutinin-stimulated T-cell response assay. Results Out of 368 patients, 41 patients (11.1%) had poor immune function, 258 patients (70.1%) had normal immune function, and 69 patients (18.7%) had strong immune function. The primary outcome of all-cause mortality or cardiac transplantation occurred in 63.4%, 45.3%, and 34.8% in the poor immunity, normal immunity, and strong immune function groups, respectively. In univariate analysis, cell-mediated immune function was strongly associated with the primary outcome (P =.014). Poor immune function portended worse prognosis (hazard ratio = 2.18, 95% CI 1.01-4.70, P =.047), and strong immune function was associated with better survival (hazard ratio = 0.67, 95% CI 0.43-1.04). However, when adjusted for multiple variables in multivariate analysis, immune function status lost its overall significance to predict primary outcome (P = 0.11), but the direction to an increased risk of primary outcome was maintained in the poor immune function group. Conclusions Poor cell-mediated immune function measured by a clinically available assay could be associated with more adverse long-term prognosis in patients with advanced heart failure. © 2016 Elsevier Inc.LICENSElicense.txtlicense.txttext/plain; charset=utf-81702https://repositorioacademico.upc.edu.pe/bitstream/10757/622259/1/license.txt255616c2e22876c8a237cd50f1bc22a3MD51falseORIGINAL10.1016j.ahj.2016.09.008.pdf10.1016j.ahj.2016.09.008.pdfapplication/pdf200419https://repositorioacademico.upc.edu.pe/bitstream/10757/622259/2/10.1016j.ahj.2016.09.008.pdfe6d01603d18f137819bac0da82c58978MD52trueTEXT10.1016j.ahj.2016.09.008.pdf.txt10.1016j.ahj.2016.09.008.pdf.txtExtracted Texttext/plain3965https://repositorioacademico.upc.edu.pe/bitstream/10757/622259/3/10.1016j.ahj.2016.09.008.pdf.txtd101c8f48d52110e2433ce03e252dfe3MD53falseTHUMBNAIL10.1016j.ahj.2016.09.008.pdf.jpg10.1016j.ahj.2016.09.008.pdf.jpgGenerated Thumbnailimage/jpeg85976https://repositorioacademico.upc.edu.pe/bitstream/10757/622259/4/10.1016j.ahj.2016.09.008.pdf.jpg7620e6f343bc063fc746055557d16a9bMD54falseelsevier-thumbnail.pngapplication/octet-stream77416https://repositorioacademico.upc.edu.pe/bitstream/10757/622259/5/elsevier-thumbnail.png77c7e9a562c4c4736093e27568f8f71aMD55false10757/622259oai:repositorioacademico.upc.edu.pe:10757/6222592026-02-17 17:40:12.63Repositorio Académico UPCupc@openrepository.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
score 13.942879
Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).

Ejemplares Similares